Marcela V. Maus is a professor of medicine at Harvard Medical School and director of the Cellular Immunotherapy Program at Massachusetts General Hospital.
She earned her MD–PhD at the University of Pennsylvania, where she trained in the laboratory of Carl H. June, developing methods to expand T-cell populations, for medical therapies.
[6] Maus has used CRISPR-Cas9 to develop the CAR-T cells that incorporate a molecule called Bi-specific T-cell engager (BiTE).
[10] Maus is on the leadership team of MicroMedicine, a start-up which creates automated microfluidics for targeted cell isolation from biological fluids.
[4][11] Maus was awarded a Damon Runyon Cancer Research Foundation Stage 2 fellowship to develop CAR-T cells that can target abnormal antigens made from oncogenes.